Helix BioPharma closes C$3.7M convertible debenture private placement at 25% interest
What's the deal? Helix BioPharmaDealroom has a profile for this one. Try Dealroom → Corp., a clinical-stage oncology company listed on the TSX, has closed a non-brokered private placement of unsecured convertible debentures, raising C$3,673,000 in gross proceeds. The company issued 3,673 debentures, which carry a 25% annual interest rate and mature 14 months from closing.
If not repaid by maturity, holders can convert the principal into common shares at C$1.42 per share — a 20% discount to market price under TSX policies. Accrued unpaid interest can also be converted into shares at the greater of that conversion price or a volume-weighted average trading price minus the TSX-permitted discount.
No finder's fees were paid, and all securities are subject to a four-month hold period.
Why now? Helix said the proceeds will fund general working capital and advance its drug development pipeline. The company's lead asset is L-DOS47, an antibody-enzyme conjugate designed to prime hard-to-treat tumours for increased sensitivity to therapy. It has completed Phase Ib studies in non-small cell lung cancer.
Helix is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator targeting post-transplant leukaemia relapse, and GEMCEDA, an oral gemcitabine prodrug for advanced cancers. All three programmes need capital to progress.
What could go wrong? A 25% annual interest rate signals the company is paying a steep price for capital — typical for small clinical-stage biotechs with limited financing options. If Helix cannot repay by maturity, conversion at a discount would dilute existing shareholders.
The company's pipeline is still early-stage, with no approved products generating revenue. Clinical and regulatory setbacks could erode the value of the shares underlying the debentures.
The signal: Helix BioPharma's willingness to accept a 25% annual interest rate underscores how constrained capital markets remain for early-growth, pre-revenue oncology firms. With no approved products and multiple programmes requiring funding, the company had little leverage to negotiate better terms — a dynamic increasingly common among small-cap biotechs competing for investor attention against later-stage peers with de-risked pipelines.
Read more: Stockwatch
